GxP & NIST Cybersecurity Transformation
Prevvi Team
Client
A clinical-stage biotechnology company
Industry
Life Sciences
What was delivered
- GxP data controls
- AWS S3 and IAM architecture
- Computer system validation
- NIST maturity assessments
- Security policy and remediation
- Backup, retention, and audit readiness
Founder-led enterprise project. This work was delivered by Prevvi's founder in an in-house leadership role before Prevvi was founded. It is shared here as part of the experience behind how Prevvi operates, not as a Prevvi client engagement.
Before founding Prevvi, our founder led IT at a clinical-stage biotechnology company preparing its science for regulated development. Two mandates ran in parallel: build clinical data infrastructure that could stand behind future FDA submissions, and raise the company’s cybersecurity maturity fast enough to match its growth. This case study covers both, because in a regulated life sciences company they are inseparable.
The challenge
A clinical-stage biotech lives and dies by the integrity of its data. Raw scientific and clinical data must be protected not just from loss but from undetected alteration, because regulators expect evidence that data has remained trustworthy across its entire life. At the same time, the company’s security posture had to mature quickly: investors, partners, and auditors all measure it, and a NIST maturity around 2.0 signals processes that exist but do not reliably operate.
The twin goals: GxP-aligned data infrastructure, and a NIST cybersecurity maturity moved from approximately 2.0 to 4.0 within six months.
What was delivered
GxP-compliant clinical data infrastructure
- GxP data controls protecting raw data integrity for regulated research
- AWS S3 architecture and IAM design for clinical and scientific data, with access scoped to defined roles
- Computer system validation practices, so systems handling regulated data were documented as fit for purpose
- Data-transfer agreements governing how data moved between parties
- Backup and retention aligned to regulatory expectations, and audit readiness so evidence could be produced on request
Cybersecurity maturity transformation
- NIST assessments establishing the baseline and measuring progress
- Risk remediation prioritized by impact
- Identity improvements and endpoint controls across the organization
- Security policies written and operationalized
- Vendor management and backup and recovery brought under governance
- Ongoing governance so the gains persisted after the push
How it was approached
Data integrity as the organizing principle
GxP work anchors on a simple question: can you prove this data is what it claims to be? Every architectural choice, access scoped through IAM, transfers under agreement, validated systems, retention with audit trails, flows from making that answer yes. Building infrastructure around integrity first also simplifies security, because the controls that protect data from attackers and the controls that protect it from silent corruption largely overlap.
Maturity means operating, not owning
The difference between NIST maturity 2.0 and 4.0 is not buying more tools. It is the difference between controls that exist somewhere and controls that run, get measured, and improve. The six-month transformation focused on making practices repeatable and governed: policies people follow, assessments on a cadence, remediation tracked to closure, vendors managed rather than trusted.
Sequence by risk, not by convenience
Six months is short. The roadmap ordered work by what reduced the most risk soonest, identity and endpoints early, then policy depth, vendor governance, and recovery capability, so every month ended with the company measurably safer than the last.
What GxP means for IT
GxP is shorthand for the “good practice” quality regulations, such as GLP, GCP, and GMP, that govern regulated life sciences work. For IT infrastructure, GxP translates into concrete obligations:
- Data integrity: often summarized by the ALCOA principles, data should be attributable, legible, contemporaneous, original, and accurate
- Validation: systems that touch regulated data must be shown, with documentation, to do what they are supposed to do
- Access control: who can create, modify, or delete records must be defined and enforced
- Retention and auditability: records must survive, unaltered, for their required lifetime, and you must be able to demonstrate it
If your company is heading toward regulated development, building these habits early is dramatically cheaper than retrofitting them under deadline.
The outcome
The company gained clinical data infrastructure designed to preserve scientific data integrity and support regulated development, and a cybersecurity program whose NIST maturity rose from approximately 2.0 to 4.0 in six months. In a related effort, the same IT leadership built internal capability that replaced an expensive outsourced support model, lowering IT operating costs by approximately 30%.
These practices, integrity-first data architecture, least-privilege access, security that operates rather than merely exists, are the foundation Prevvi now brings to its life sciences clients through our IT compliance services.
Key takeaways
- In regulated life sciences, data integrity is the organizing principle for both infrastructure and security.
- Maturity gains come from making controls operate on a cadence, not from acquiring tools.
- Sequence a transformation by risk reduction per month.
- GxP habits built early cost a fraction of GxP retrofits under regulatory pressure.
Frequently asked questions
GxP covers the good-practice quality regulations (GLP, GCP, GMP) for regulated life sciences work. For IT it means concrete obligations: data integrity per the ALCOA principles, documented validation showing systems do what they claim, enforced access control over who can create or change records, and retention with audit trails for each record's required lifetime.
Organizations commonly score their NIST CSF implementation on a tiered maturity scale. Around 2.0, controls exist but operate inconsistently; around 4.0, practices are repeatable, measured, governed, and improving. Moving up the scale is about making controls operate on a cadence, not about buying more tools.
This transformation moved a clinical-stage biotech from approximately 2.0 to 4.0 in six months by sequencing work by risk: identity and endpoint controls first, then policy depth, vendor governance, and recovery capability. Timelines vary with starting posture and company size, but risk-ordered sequencing is what makes fast timelines possible.
CSV is the documented process of demonstrating that a system handling regulated data is fit for its intended use: requirements, testing, and evidence that it does what it is supposed to do. Regulators expect it for systems that touch GxP data, and retrofitting it later costs far more than building the habit early.
Before regulated development forces the issue. Integrity-first data architecture, scoped access, validated systems, and governed retention are dramatically cheaper to build early than to retrofit under a regulatory deadline, and the same controls double as security controls from day one.
Have a similar project in mind?
Talk to a real engineer about your environment: no sales script, just straight answers on how we would approach it.
